These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 23791707)

  • 21. An improved cell-based method for determining the γ-secretase enzyme activity against both Notch and APP substrates.
    McKee TD; Loureiro RM; Dumin JA; Zarayskiy V; Tate B
    J Neurosci Methods; 2013 Feb; 213(1):14-21. PubMed ID: 23219895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The search for gamma-secretase and development of inhibitors.
    Tsai JY; Wolfe MS; Xia W
    Curr Med Chem; 2002 Jun; 9(11):1087-106. PubMed ID: 12052174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extracellular interface between APP and Nicastrin regulates Aβ length and response to γ-secretase modulators.
    Petit D; Hitzenberger M; Lismont S; Zoltowska KM; Ryan NS; Mercken M; Bischoff F; Zacharias M; Chávez-Gutiérrez L
    EMBO J; 2019 Jun; 38(12):. PubMed ID: 31109937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective amyloid-beta lowering agents.
    Wolfe MS
    BMC Neurosci; 2008 Dec; 9 Suppl 2(Suppl 2):S4. PubMed ID: 19090992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel γ-secretase modulators: a review of patents from 2008 to 2010.
    Pettersson M; Kauffman GW; am Ende CW; Patel NC; Stiff C; Tran TP; Johnson DS
    Expert Opin Ther Pat; 2011 Feb; 21(2):205-26. PubMed ID: 21231889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An NSAID-like compound, FT-9, preferentially inhibits gamma-secretase cleavage of the amyloid precursor protein compared to its effect on amyloid precursor-like protein 1.
    Sala Frigerio C; Kukar TL; Fauq A; Engel PC; Golde TE; Walsh DM
    Biochemistry; 2009 Nov; 48(46):10894-904. PubMed ID: 19821615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. γ-Secretase modulator in Alzheimer's disease: shifting the end.
    Xia W; Wong ST; Hanlon E; Morin P
    J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of γ-Secretase Trimming Activity by Topological Changes of Transmembrane Domain 1 of Presenilin 1.
    Cai T; Yonaga M; Tomita T
    J Neurosci; 2017 Dec; 37(50):12272-12280. PubMed ID: 29118109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta-amyloid precursor protein mutants respond to gamma-secretase modulators.
    Page RM; Gutsmiedl A; Fukumori A; Winkler E; Haass C; Steiner H
    J Biol Chem; 2010 Jun; 285(23):17798-810. PubMed ID: 20348104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dissociation between the processivity and total activity of γ-secretase: implications for the mechanism of Alzheimer's disease-causing presenilin mutations.
    Quintero-Monzon O; Martin MM; Fernandez MA; Cappello CA; Krzysiak AJ; Osenkowski P; Wolfe MS
    Biochemistry; 2011 Oct; 50(42):9023-35. PubMed ID: 21919498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein.
    Yang T; Arslanova D; Gu Y; Augelli-Szafran C; Xia W
    Mol Brain; 2008 Nov; 1():15. PubMed ID: 18983676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NSAID-based γ-secretase modulators do not bind to the amyloid-β polypeptide.
    Barrett PJ; Sanders CR; Kaufman SA; Michelsen K; Jordan JB
    Biochemistry; 2011 Nov; 50(47):10328-42. PubMed ID: 21995415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The lipidome associated with the γ-secretase complex is required for its integrity and activity.
    Ayciriex S; Gerber H; Osuna GM; Chami M; Stahlberg H; Shevchenko A; Fraering PC
    Biochem J; 2016 Feb; 473(3):321-34. PubMed ID: 26811537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Membrane trafficking and proteolytic activity of γ-secretase in Alzheimer's disease.
    Kanatsu K; Tomita T
    Biol Chem; 2016 Sep; 397(9):827-35. PubMed ID: 27390881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect β-secretase inhibitors.
    Gay M; Evrard C; Descamps F; Carato P; Renault N; Coevoet M; Eddarkaoui S; Baud C; Larchanché PE; Buée L; El Bakali J; Vingtdeux V; Sergeant N; Melnyk P
    Eur J Med Chem; 2018 Nov; 159():104-125. PubMed ID: 30268822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analyzing Amyloid-β Peptide Modulation Profiles and Binding Sites of γ-Secretase Modulators.
    Trambauer J; Fukumori A; Kretner B; Steiner H
    Methods Enzymol; 2017; 584():157-183. PubMed ID: 28065262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
    Pollack SJ; Lewis H
    Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toward the structure of presenilin/γ-secretase and presenilin homologs.
    Wolfe MS
    Biochim Biophys Acta; 2013 Dec; 1828(12):2886-97. PubMed ID: 24099007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.